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Abstract: Claudins are major integral membrane proteins of tight junctions. Altered 
expression of several claudin proteins, in particular claudin-1, -3, -4 and -7, has been linked 
to the development of various cancers. Although their dysregulation in cancer suggests that 
claudins play a role in tumorigenesis, the exact underlying mechanism remains unclear. 
The involvement of claudins in tumor progression was suggested by their important role in 
the migration, invasion and metastasis of cancer cells in a tissue-dependent manner. Recent 
studies have shown that they play a role in epithelial to mesenchymal transition (EMT), the 
formation of cancer stem cells or tumor-initiating cells (CSCs/TICs), and chemoresistance, 
suggesting that claudins are promising targets for the treatment of chemoresistant   
and recurrent tumors. A recently identified claudin-low breast cancer subtype that is 
characterized by the enrichment of EMT and stem cell-like features is significantly 
associated with disease recurrence, underscoring the importance of claudins as predictors 
of tumor recurrence. The critical role of epigenetic mechanisms in the regulation of claudin 
expression indicates the possible application of epigenetic therapy to target claudins. A 
better understanding of the emerging role of claudins in CSC/TICs and chemoresistance 
may help to develop therapies against recurrent cancers. 
Keywords: claudin; cancer; epithelial to mesenchymal transition (EMT); cancer   
stem cells or tumor-initiating cells (CSC/TICs); chemoresistance; tumor recurrence; 
epigenetic regulation 
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1. Introduction 
Claudins are transmembrane proteins and important components of tight junctions (TJs), which are 
central for the regulation of paracellular permeability and the maintenance of epithelial cell   
polarity [1,2]. Their expression is altered in various cancers compared to normal tissues, and claudin-1, 
-3, -4 and -7 are among the most frequently dysregulated members of the claudin family [1,3]. The 
downregulation of several claudins in cancer is consistent with the disruption of TJs during 
tumorigenesis. However, claudin overexpression, particularly that of claudin-3 and claudin-4, has been 
reported in various cancers. The dysregulated expression of claudins in cancer occurs at both 
transcriptional and post-transcriptional levels [3]. Recently, accumulating evidence indicates that 
epigenetic mechanisms including DNA methylation, histone modification or microRNAs (miRNAs) 
are crucial for the regulation of claudin expression in addition to the previously reported transcriptional 
regulation by transcription factors [4–7]. Claudins can play a cancer-promoting or tumor suppressor 
role in a tissue-dependent manner, and their expression is associated with prognosis in several cancers, 
suggesting their utility as prognostic factors as well as therapeutic targets [1,3].  
One of the main challenges in cancer therapy is overcoming chemoresistance and recurrence after 
initial treatment, which are partly responsible for the high mortality of several cancers. Recent studies 
have demonstrated the heterogeneity of tumors and suggested that a small population of cells with  
self-renewal potential—termed cancer stem cells or tumor-initiating cells (CSC/TICs)—play a crucial 
role in chemoresistance and recurrence, as well as in tumor formation [8]. This population of cells can 
be generated from differentiated cells (non-CSC/TICs) through epithelial to mesenchymal transition 
(EMT) [9]. In light of these observations, the existence of an axis between EMT, CSC/TICs and drug 
resistance was proposed [9].  
Recently, a new claudin-low molecular subtype of breast cancer was identified that is characterized 
by low expression of tight junction and adherens proteins, including claudin-3, -4 and -7, and   
E-cadherin (CDH1) [10], and enriched in stem-like and EMT features [11,12]. In accordance with the 
role of EMT and CSC/TICs in cancer, this subtype is associated with poor prognosis of patients with 
high-grade invasive ductal breast carcinoma [13]. Furthermore, a growing number of studies suggest 
that claudins are involved in the regulation of CSC/TICs and chemoresistance [14–18]. These 
observations indicate that claudins may contribute to drug resistance and tumor recurrence through a 
mechanism involving EMT and CSC/TICs.  
This review summarizes current knowledge on the dysregulation of claudins in human cancer and 
the regulatory mechanisms involved, focusing on epigenetic mechanisms whose importance in the 
regulation of claudin expression has been supported by recent growing evidence. In addition, the 
involvement of claudins in tumor progression, in particular their emerging roles in EMT and the 
formation of CSC/TICs, and the link between claudins, CSC/TICs and drug resistance or tumor 
recurrence are described. Finally, therapeutic strategies targeting claudins in cancer treatment are 
briefly discussed. A better understanding of the role of claudins in the regulation of CSC/TICs   
and chemoresistance may be of value for the design of therapeutic strategies for the treatment of  
recurrent tumors. Int. J. Mol. Sci. 2013, 14 18150 
 
 
2. Tight Junctions  
Tight junctions (TJs), together with adherens junctions and desmosomes, form the apical junctional 
complex that mediates cell-cell adhesion in epithelial and endothelial cells [19]. While adherens 
junctions and desmosomes mainly contribute to mechanical adhesion between adjacent cells, TJs are 
involved in several cellular functions. They play a critical role in the maintenance of cell polarity by 
forming a boundary between apical and basolateral membranes, and they control paracellular ion 
flux [19]. In addition, their involvement in various signaling pathways indicates that they function in 
the regulation of cell proliferation, gene expression and differentiation [19–21].  
TJs are composed of integral transmembrane and peripheral membrane proteins involved in 
complex protein-protein interactions [19,21]. The integral transmembrane proteins include occludins, 
claudins, junctional adhesion molecules (JAMs), which contain a single transmembrane domain, and 
the single pass membrane proteins Crumbs 3 (CRB3) and coxackievirus and adenovirus receptor 
(CAR) [19,21]. Tricellulin, a four transmembrane domain protein, was recently identified as a novel 
integral protein [22]. Peripheral proteins located in cytoplasmic regions include zonula occludens 
(ZOs) and other PDZ domain-containing proteins, as well as regulatory and signaling proteins that link 
transmembrane TJ proteins to the cytoskeleton and regulate various signaling pathways [19,20]. 
Various associated proteins regulate TJ formation and cell polarization by controlling the 
transcription and localization of other TJ proteins. Two signaling complexes, the CRB3/protein 
associated with Lin seven 1 (PALS1)/PALS1-associated tight junction protein (PATJ) complex and the 
cdc42-interacting partitioning defective 3 (Par3)/partitioning defective 6 (Par6)/atypical protein kinase 
C (aPKC) complex, are important in the regulation of junctional polarity and assembly [21]. In 
addition to these complexes, scribble complex is also known to regulate cellular polarity and TJ 
formation in mammalian epithelial cells [23]. Interestingly, a recent study [24] reported that cell 
polarity regulator scribble regulates TAZ, which is a downstream effector of the hippo pathway and is 
required for self-renewal and tumorigenic potential of breast CSC/TICs, suggesting a link between cell 
polarity and hippo pathway in breast cancer cells. This study indicated that EMT-induced scribble 
delocalization from the cell membrane promotes the acquisition of breast CSC/TIC features by 
activating TAZ. Rab 13, a member of the small GTPase Rab family of proteins, also plays a role in TJ 
assembly by regulating the localization of TJ proteins including claudin-1 and ZO-1 to the plasma 
membrane and the protein kinase A (PKA)-dependent phosphorylation of proteins necessary for TJ 
barrier function [19].  
In addition, TJ proteins are involved in cell proliferation and gene expression by modulating 
signaling cascades, or by sequestrating transcription factors and cell cycle regulators [20,21]. Occludin 
is linked to Raf, an effector of Ras signaling, and is also connected to Rho A signaling [21]. Occludin 
is involved in transforming growth factor-β (TGF-)-induced EMT, which requires a loss of cell 
polarity and disruption of the TJ barrier [19,21]. The ZO-1-associated nucleic acid-binding protein 
(ZONAB), which is localized in both TJs and nuclei, is a Y-box transcription factor protein that 
regulates gene transcription and cell proliferation through interaction with the TJ protein ZO-1, the 
regulator of cell proliferation cell division kinase 4 (CDK4), or with Ras-like GTPase (RalA)   
proteins [21]. Generally, the assembly of TJs suppresses cell proliferation by inhibiting several 
proliferation promoting pathways such as Raf-1 signaling and the ZONAB-CDK4 pathway [20].  Int. J. Mol. Sci. 2013, 14 18151 
 
 
TJ-associated proteins such as ZO-2, membrane-associated guanylate kinase with inverted domain 
structure 1 (MAGI-1), and multi-PDZ domain protein 1 (MUPP1) inactivate viral oncogenes, and the 
interaction between the tumor suppressor PTEN and TJ adaptors—including MAGI-2 and   
MAGI-3—inhibits protein kinase B/Akt-induced cell invasiveness, suggesting that these TJ proteins 
play a role in carcinogenesis [19,20]. Changes in the activity of the ZO-2 interacting transcription 
factor AP-1 are associated with certain cancers, suggesting that TJ-associated signaling is dysregulated 
in cancer cells [19,25]. The regulation of the expression of the proto-oncogene ErbB2 by   
ZONAB [19,20] and alterations in the expression of TJ-associated proteins during tumorigenesis 
further support the possibility that these proteins are involved in tumorigenesis. ZO-1 and ZO-2 
expression is altered in some cancers, and ZO-1 expression is associated with the prognosis of breast 
cancer patients [25]. However, whether these changes can induce tumorigenesis or if they are 
consequences of tumorigenesis remains unclear. Thus, further studies are needed to determine the role 
of TJ proteins in carcinogenesis. 
3. Claudins 
Claudins are major integral membrane proteins of TJs and include 24 family members in   
mammals [2]. In humans, 23 of the 24 claudin genes (the exception is CLDN13) have been identified 
(Table 1), while all 24 members have been detected in mice and rats [2]. CLDN genes have few introns 
and are typically small, i.e., several kilobases (kbs). The human genome contains pairs of CLDN genes 
that have similar sequences and are located in close proximity, such as CLDN6 and CLDN9 on 
chromosome 16, CLDN22 and CLDN24 on chromosome 4, CLDN8 and CLDN17 on chromosome 21, 
and CLDN3 and CLDN4 on chromosome 7 (Table 1). This suggests that some claudin genes were 
generated by gene duplication, and that adjacent genes may be coordinately regulated [2]. Phylogenetic 
tree analyses of human claudin proteins also showed sequence similarities between some claudins, 
such as claudin-22 and claudin-24, claudin-6 and claudin-9, and claudin-3 and claudin-4, whereas 
other claudins show relatively distant relationships [2]. 
Most claudin proteins are within the 20–34 kDa size range (Table 1) and are reported to have four 
transmembrane helices with amino- and carboxyl-terminal tails extending into the cytoplasm [2,26]. In 
addition, claudin proteins have two extracellular loops; the first extracellular loop contains charged 
amino acids and plays a crucial role in paracellular ion selectivity [26]. The carboxy-terminal tails of 
claudins, which mostly differ in size and sequence between different claudin proteins, contain a   
PDZ-domain-binding motif that allows claudins to interact directly with cytoplasmic TJ-associated 
proteins such as ZO-1, ZO-2, ZO-3, and MUPP1. Moreover, this tail region is the site of   
post-translational modifications such as phosphorylation, which can affect the localization and 
functions of claudins. Phosphorylation of claudin-1 by mitogen-activated protein kinase (MAPK) [27] 
or protein kinase C (PKC) [28], and cyclic AMP (cAMP)-induced phosphorylation of claudin-5 [29] 
promote the barrier function of TJs. By contrast, PKA-mediated phosphorylation of claudin-16 
increases Mg
2+ transport [30]. Other proteins such as mutant WNK lysine-deficient protein kinase 4 
(WNK4) also increase paracellular permeability by phosphorylating claudins [31].  Int. J. Mol. Sci. 2013, 14 18152 
 
 
Table 1. Human claudin genes and protein information. 
Gene 
Chromosomal 
location 
Transcript 
Protein size  
(amino acids) 
Molecular weight 
(Da) 
CLDN1 3q28-q29  NM_021101.3 211  22,744 
CLDN2 Xq22.3-q23  NM_020384.2  230  24,549 
CLDN3 7q11.23  NM_001306.3  220  23,319 
CLDN4 7q11.23  NM_001305.3  209  22,077 
CLDN5  22q11.21 NM_001130861.1 
NM_003277.3 
218 23,147 
CLDN6  16p13.3 NM_021195.4  220  23,292 
CLDN7  17p13 NM_001307.4  211   
158 
22,390  
16,837 
CLDN8  21q22.11 NM_199328.1  225  24,845 
CLDN9  16p13.3 NM_020982.2  217  22,848 
CLDN10  13q31-q34 NM_182848.2 
NM_006984.3 
226  
228 
24,251  
24,488 
CLDN11  3q26.2-q26.3 NM_005602.5  207  21,993 
CLDN12  7q21 NM_012129.2  244  27,110 
CLDN14  21q22.3 NM_144492.1 
NM_012130.2 
239 25,699 
CLDN15  7q11.22 NM_014343.1  228  24,356 
CLDN16  3q28 NM_006580.2  305  33,836 
CLDN17  21q22.11 NM_012131.1  224  24,603 
CLDN18  3q22.3 NM_001002026.2 
NM_016369.3 
261  
261 
27,856  
27,720 
CLDN19  1p34.2 NM_001123395.1 
NM_148960.2 
224  
211 
23,229  
22,077 
CLDN20  6q25 NM_001001346.2  219  23,515 
CLDN21  4q35.1 NA  NA  NA 
CLDN22  4q35.1 NM_001111319.1 220  24,509 
CLDN23  8p23.1 NM_194284.2  292  31,915 
CLDN24  4q35.1 XM_001714660.1  205  22,802 
The chromosomal location and transcript information (refseq number) of CLDN genes were obtained from 
the National Center for Biotechnology Information site (http://www.ncbi.nlm.nih.gov/). Information on the 
claudin proteins including protein size and molecular weight were obtained from Universal Protein Resource 
(UniProt; http://www.uniprot.org/). NA: not available. 
The expression pattern of claudins varies among tissue types, and most tissues or cell types express 
multiple claudins [32,33]. Such multiple combinations of claudin expression contribute to the 
formation of TJs through their homotypic or heterotypic interactions, or their interaction with other TJ 
proteins [32]. Claudins play a crucial role in the regulation of the selectivity of paracellular 
permeability, with claudin-2 and claudin-15 known to function in cation channels/pores, whereas 
claudin-4, -7 and -10a contribute to the function of anion channels/pores [22]. Claudin overexpression 
in several cell lines affects transepithelial resistance (TER) and the permeability to different ions in a 
claudin-specific manner. Claudin-1, -4, -5 and -7 increase TER, whereas claudin-2 and claudin-10 
decrease TER in cultured epithelial cells [22]. Moreover, claudin-4 overexpression alters Na
+ Int. J. Mol. Sci. 2013, 14 18153 
 
 
permeability without significant effect on Cl
− permeability in Madin-Darby canine kidney (MDCK) 
cells [34].  
Mutations in claudin genes have been linked to several human diseases. Sclerosing cholangitis and 
ichthyosis are associated with CLDN1 mutation, and hypomagnesemia and hypercalcinuria have been 
linked to mutations in CLDN16 and CLDN19  [22]. Claudin-3 and claudin-4 are receptors for the 
Clostridium perfringens enterotoxin (CPE), while claudin-1, -6 and -9 are co-receptors for the hepatitis 
C virus (HCV). 
4. Dysregulation of Claudins in Human Cancer  
4.1. Claudin Expression in Human Cancers 
Altered expression of several claudin proteins, in particular claudin-1, -3, -4 and -7, has been 
detected in various cancers (Table 2) [1,3]. Consistent with the disruption of TJs during   
tumorigenesis [1], certain claudins including claudin-1 and claudin-7 are downregulated in invasive 
breast, prostate, and esophageal cancers (Table 2). On the other hand, the upregulation of claudins, 
particularly claudin-3 and claudin-4, has also been associated with tumorigenesis. Claudin-3 and 
claudin-4 are highly overexpressed in ovarian cancer including serous carcinoma compared to normal 
ovarian tissues, and their expression is also upregulated in several other malignancies, including breast, 
gastric, pancreatic, prostate and uterine cancers (Table 2). It is important to note that the upregulation 
of claudin-3 and claudin-4 expression in ovarian cancer is based on the hypothesis that ovarian cancer 
arises from normal ovarian surface epithelium. However, recent studies have shown that most   
ovarian high-grade serous carcinomas originate from the fallopian tube rather than the ovarian surface 
epithelium [35–38]. In this context, the expression of claudins in serous ovarian carcinoma should be 
compared to that in the fallopian tube.  
Recent studies on claudins in breast cancer showed that claudin expression may be distinct within 
specific subtypes of breast cancer, such as claudin-4, whose expression is downregulated compared to 
normal mammary epithelial cells in grade 1 ductal carcinoma of the breast [39], whereas it is 
significantly upregulated in basal-like breast cancer [40]. The expression of claudin-1, -3 and -4 is 
higher in the intestinal type of gastric adenocarcinoma than in the diffuse type of gastric cancer [41]. A 
recent comprehensive analysis of the expression of claudins-1, -3, -4, -7 and -8 in high-grade invasive 
breast cancer, including several molecular subtypes, demonstrated the differential expression of 
claudins according to molecular subtype, showing increased claudin-7 and -8 in luminal tumors 
(estrogen positive) and increased claudin-1 and-4 in basal-like tumors [13]. Int. J. Mol. Sci. 2013, 14  18154 
 
Table 2. Claudin protein expression in human cancers.  
Cancer   Claudin-1  Claudin-2 Claudin-3  Claudin-4 Claudin-7  Claudin-11 
Breast 
Down [39] (invasive 
breast carcinoma)  
Up [13] (basal type of 
high-grade invasive 
ductal breast carcinoma) 
Down [42,43]  Up [44] 
Up [44]  
Up [13,40] (basal-like 
type of high-grade 
invasive ductal breast 
carcinoma)  
Down [39] (invasive 
ductal breast carcinoma of 
grade 1)  
Down [45] (invasive 
ductal breast carcinoma) 
Up [13] (luminal type of 
high-grade invasive ductal 
breast carcinoma) 
 
Cervical  Up [46]  Up [46]    Up [46]  Up [46]   
Colorectal  Up [47,48]    Up [47]  Up [47]     
Esophageal      Up [49]  Up [49]  Down [50]   
Gastric  Up [41]    Up [41]  Up [41,51]  Up [52]  Down [53] 
Liver   Down [54]           
Melanoma Up  [55]           
Ovarian  
  
Up [56–61] (normal: 
ovarian surface 
epithelium) 
Up [56,57,60–62]  Up [63]   
  
Down [64] (normal: 
fallopian tube) 
Down [64] (normal: 
fallopian tube) 
  
Prostate  Down [65]  Down [42]  Up [66]  Up [66]   Down [65]   
Pancreatic      Up  [67,68]     
Uterine      Up [69]  Up [69]     Int. J. Mol. Sci. 2013, 14 18155 
 
4.2. Regulation of Claudin Expression in Human Cancers 
The expression of claudins can be regulated by multiple mechanisms [3]. First, claudin expression 
can be regulated at the transcriptional level by transcription factors. Snail, a transcriptional repressor 
that plays a crucial role in EMT, represses the gene expression of claudins-1, -3, -4 and 7 and   
E-cadherin in mouse epithelial cells by directly binding to their promoter regions [70]. In human cell 
lines, the transcription factors Slug and Snail bind to the E-box in the promoter of human claudin-1, 
inhibiting its expression [71]. This study also showed the inverse correlation between the low 
expression level of claudin-1 and the high expression of these two transcription factors in human 
invasive breast cancer. Conversely, transcription factor RUNX3, which is a gastric tumor suppressor, 
upregulates claudin-1 expression by binding to the promoter region of CLDN1 in gastric epithelial 
cells [72]. In colon cancer cells, caudal homeobox proteins (Cdx1 & Cdx2) and GATA4 in cooperation 
with the Wnt pathway are involved in claudin-1 promoter activation [73].  
Recent studies have shown the importance of epigenetic mechanism in the transcriptional regulation 
of CLDN expression. DNA hypermethylation is associated with the downregulation of CLDN11 in 
gastric cancer cells [53] and CLDN7 in breast cancer cells [45]. The association between promoter 
DNA hypermethylation and low expression of claudin-1 was also reported in estrogen   
receptor-positive breast cancer [74]. By contrast, claudin-4 overexpression in ovarian cancer is 
associated with DNA hypomethylation, whereas gene amplification is not related to claudin-4 
expression [75]. In addition to DNA methylation, our group reported that loss of repressive histone 
methylations, including H3K27me3 and H4K20me3, is also associated with the overexpression of 
claudin-3 and claudin-4 in ovarian cancer [6] and claudin-4 in gastric cancer [7]. Our study in ovarian 
cancer [6] suggested that epigenetic derepression in addition to the well-known epigenetic inactivation 
of tumor suppressor genes may be a possible mechanism underlying the activation of cancer-associated 
genes. Another recently reported epigenetic mechanism is the regulation of CLDN expression by 
miRNAs. For example, claudin-1 mRNA and protein expression is downregulated by miR-155 in 
ovarian CSC/TICs [16].  
Studies have shown that transcription factors and epigenetic modifications cooperate in the 
transcriptional regulation of claudin levels. The Sp1 transcription factor is crucial for CLDN3 and 
CLDN4 promoter activity, and the epigenetic status, including DNA methylation and histone H3 
acetylation, in the critical region containing the Sp1 binding site also plays a role in the regulation of 
CLDN3 and CLDN4 expression in ovarian cancer cells [4,5]. DNA hypomethylation and the 
transcription factor CREB are related to the transcriptional upregulation of CLDN18  splice  
variant 2 [76]. Claudin-18 mRNA and protein levels are upregulated by treatment with   
12-O-tetradecanoylphorbol 13-acetate (TPA), a PKC activator, and this upregulation is further 
enhanced by treatment with DNA demethylating agents in human pancreatic cancer cells [77].  
Claudin expression may also be regulated at the post-transcriptional level. Claudin-1 expression 
was shown to be regulated through the modulation of mRNA stability in colon cancer cells [78], and 
further analysis by the same group showed that histone deacetylase (HDAC)-dependent regulation of 
claudin-1 mRNA stability is mediated by the binding of Hu antigen R and Tristetraprolin to the 3' UTR 
of claudin-1 mRNA [79]. On the other hand, claudin-1 expression is increased by PKC in melanoma 
cells and increased claudin-1 levels contribute to melanoma cell invasion and motility [55]. Claudin-7 Int. J. Mol. Sci. 2013, 14 18156 
 
 
expression is negatively regulated by Wnt/Tcf signaling via Sox-7 in colorectal cancer cells [80]. 
Claudin-4 expression is downregulated by TGF-, whereas Ras signaling positively regulates   
claudin-4 expression in pancreatic cancer cells [81]. Furthermore, growth factors, such as the 
epidermal growth factor, can regulate claudin expression along with TER [82]. Moreover, nonsteroidal 
anti-inflammatory drugs such as aspirin significantly decrease claudin-7 expression in association with 
p38 MAPK activation in gastric epithelial cancer cells [83].  
5. Role of Claudins in Human Cancer  
5.1. Claudins in Tumor Progression 
The altered expression of claudins in various cancers plays different roles in a tissue-specific 
manner (Table 3). Epithelial tumor cells lose TJ function, leading to the loss of cell polarity and 
impairment of epithelial integrity during tumorigenesis [1,84]. Accordingly, loss of claudin expression 
was assumed to contribute to tumor progression in association with the loss of cell adhesion [1,3]. 
However, a number of studies have shown that increased expression of claudins may promote tumor 
progression through its positive effect on cell migration, invasion and metastasis (Table 3). In addition 
to such aberrant expression, the mislocalization of claudin proteins may contribute to their role in 
tumorigenesis. For example, delocalization of claudin-1 and claudin-4 from TJs in bladder tumors [85] 
and the effects of altered localization of claudin-7 on the invasiveness of esophageal carcinoma [84] 
have been reported. Additionally, the function of claudins is regulated by post-translational 
modifications such as phosphorylation. Phosphorylation of serine and/or threonine sites in the 
carboxyl-terminal domains of claudins by PKA or PKC can influence their role in cancer cells, as in 
ovarian cancer cells, where it increases paracellular permeability [86,87]. Several signaling pathways 
are involved in the roles of claudins in tumorigenesis [3]. The detailed function of some claudins 
reporting their significant roles in various cancers will be described in the next sections. 
Table 3. Roles of claudins in human cancer. 
Claudins Cancer  Function 
In vitro or  
in vivo 
Role References 
Claudin-1 
Breast   Increase of cell migration  In vitro  Cancer promoting  [88] 
Breast   Anti-apoptotic effect  In vitro  Cancer promoting  [89] 
Colon  Increase of invasion and 
metastatic behavior 
In vitro &  
in vivo 
Cancer promoting  [48] 
Liver   Increase of invasion  In vitro  Cancer promoting   [90] 
Liver   Induction of EMT  In vitro  Cancer promoting  [91] 
Melanoma  Increase of cell motility and 
invasion 
In vitro  Cancer promoting  [55] 
Oral   Increase of invasion  In vitro  Cancer promoting  [92] 
Gastric   Inhibition of tumorigenicity  In vivo  Tumor suppressive  [72] 
Lung  Inhibition of cell migration 
and invasion, in vivo 
metastasis 
In vitro &  
in vivo 
Tumor suppressive  [93] Int. J. Mol. Sci. 2013, 14 18157 
 
 
Table 3. Cont. 
Claudins Cancer  Function 
In vitro or  
in vivo 
Role References 
Claudin-3 
Ovarian   Increase of invasion  In vitro  Cancer promoting  [94] 
Ovarian Promoting  in vivo tumor 
growth and metastasis 
In vivo  Cancer promoting  [95] 
Ovarian Inhibition  of  in vivo tumor 
growth and metastasis 
In vitro &  
in vivo 
Tumor suppressive  [64] 
Ovarian  Suppression of EMT  In vitro &  
in vivo 
Tumor suppressive  [96] 
Claudin-4 
Ovarian   Increase of invasion  In vitro  Cancer promoting  [94] 
Ovarian Stimulation  of  angiogenesis In vitro &  
in vivo 
Cancer promoting  [97] 
Gastric  Inhibition of migration and 
invasion 
In vitro  Tumor suppressive  [7] 
Ovarian  Suppression of EMT  In vitro &  
in vivo 
Tumor suppressive  [96] 
Pancreatic  Suppression of cell invasion 
and metastasis 
In vitro &  
in vivo 
Tumor suppressive  [81] 
Claudin-6 
Gastric Increase  of  proliferation, 
migration and invasion 
In vitro  Cancer promoting  [98] 
Breast  Inhibition of anchorage-
independent growth 
In vitro  Tumor suppressive  [99] 
Breast  Inhibition of anchorage-
independent growth, 
migration and invasion 
In vitro  Tumor suppressive  [100] 
Claudin-7 
Colorectal Increase  of cell proliferation 
and tumorigenicity 
In vitro &  
in vivo 
Cancer promoting  [80] 
Ovarian   Increase of invasion  In vitro  Cancer promoting  [101] 
Esophageal  Decrease of cell growth and 
invasion 
In vitro  Tumor suppressive  [84] 
Lung  Inhibition of migration  
and invasion, in vivo  
tumor growth 
In vitro &  
in vivo 
Tumor suppressive  [102] 
Claudin-11 
Bladder   Inhibition of cell invasion  In vitro  Tumor suppressive  [103] 
Gastric  Inhibition of cell invasion  In vitro   Tumor suppressive  [53] 
5.1.1. Claudin-1 
Claudin-1 is one of the most dysregulated claudins in human cancers, and its crucial role in various 
cancers has been described (Table 3). Claudin-1 can function as a cancer-promoting and tumor 
suppressor factor depending on cancer type. 
The cancer-promoting role of claudin-1 via its effect on invasion or motility of cancer cells has been 
described in various cancers. Claudin-1 significantly increases xenograft tumor growth and metastatic 
behavior in athymic mice through its effects on E-cadherin expression and β-catenin/Tcf signaling in Int. J. Mol. Sci. 2013, 14 18158 
 
 
colon carcinoma [48]. This study also showed that claudin-1 expression increases in colon cancer, in 
particular in metastastic tissues with mislocalization from the cell membrane to the cell nucleus and 
cytoplasm. Claudin-1 overexpressing colon cancer cells formed more colonies in soft agar than did 
control cells and increased the activity of matrix metalloproteinases (MMPs). In contrast, inhibition of 
claudin-1 expression significantly decreased the anchorage-independent growth and invasion of 
metastatic colon cancer cells with a significant decrease in MMP-9 activity. In oral squamous cell 
carcinoma cells, claudin-1 promotes invasion by upregulating the activity of MMP [92]. Similarly, 
claudin-1 expression induces MMP-2 activation, resulting in increased cell invasion and motility in 
melanoma cells [55]. In this study, claudin-1 expression was increased at the mRNA and protein levels 
by PKC activation, while the inhibition of PKC signaling decreased claudin-1 expression. In human 
liver cells, claudin-1 promotes invasive behavior by activating the c-Abl-PKC signaling pathway [90]. 
Recently, Suh et al. [91] in the same group further revealed that the induction of EMT by claudin-1 
requires the activation of the c-Abl-Ras-Raf-1/ERK1/2 signaling pathway in human liver cells, 
supporting the importance of c-Abl signaling in the claudin-1-induced acquisition of a malignant 
phenotype. Claudin-1 knockdown in basal-like breast cancer cells decreases cell migration by affecting 
the expression of genes involved in EMT [88].  
On the other hand, claudin-1 has an anti-apoptotic effect in tamoxifen-treated human breast cancer 
MCF-7 cells [89].  
Conversely, the tumor suppressive activity of claudin-1 was reported in gastric cancer [72] and lung 
cancer [93]. Knockdown of claudin-1 in gastric cancer cells increases in vivo tumorigenicity [72], and 
claudin-1 overexpression suppresses metastasis as well as cell migration and invasion of lung cancer 
cells [93]. 
5.1.2. Claudin-3 and Claudin-4 
Because of the frequent dysregulation of claudin-3 and claudin-4 in ovarian cancer cells, the role of 
these claudins has mainly been reported in ovarian cancer (Table 3). In particular, overexpression of 
claudin-3 or claudin-4 in ovarian cancer is based on the hypothesis that ovarian cancers originate from 
normal ovarian surface epithelial cells, which do not express claudin-3 or claudin-4. Therefore, the 
overexpression of claudin-3 or claudin-4 has been shown to promote the progression of ovarian cancer. 
Forced expression of claudin-3 and claudin-4 in ovarian epithelial cells increases invasive behavior by 
inducing the activation of MMP [94]. CLDN3 small interfering RNA (siRNA) inhibits tumor growth 
and metastasis in mouse and human ovarian tumor xenografts, further supporting the cancer-promoting 
role of claudin-3 [95]. Claudin-4 promotes the production of factors that stimulate angiogenesis both  
in vitro and in vivo, suggesting its pro-angiogenic role in ovarian cancer [97]. A recent study showed 
that claudin-4 promotes the motility of breast or ovarian cancer cells through interactions of its second 
extracellular loop with extracellular matrix proteins [104]. 
However, the opposite function of claudin-3 and claudin-4 in ovarian cancer was recently reported 
by Shang et al. [64]. In this study, knockdown of claudin-3 and claudin-4 enhanced in vivo tumor 
growth and lung metastasis, whereas a significant growth increase was not observed in vitro. TJ 
formation and cell adhesion is impaired in claudin-3 and claudin-4 knockdown ovarian cancer cells. 
Loss of claudin-3 or claudin-4 expression increases in vitro cell migration and invasion in line with Int. J. Mol. Sci. 2013, 14 18159 
 
 
their effect on enhancing metastasis in vivo. Moreover, this phenomenon is associated with 
downregulation of E-cadherin and activation of β-catenin signaling. Based on these results, this study 
concluded that both claudin-3 and claudin-4 inhibit tumor growth and metastatic potential in vivo 
through the maintenance of E-cadherin expression and suppression of β-catenin signaling, suggesting a 
tumor suppressive role for claudin-3 and claudin-4 in ovarian cancer. This study also examined the 
expression of claudin-3 and claudin-4 in the distal fallopian tube and in tumors from the same patients 
in six cases of serous ovarian cancer, and high expression of these claudins in both sites was observed 
in all six patients, suggesting that claudin-3 and claudin-4 are normally expressed in the fallopian tube, 
and downregulation of claudin-3 or claudin-4 in ovarian cancer promotes tumor growth and metastatic 
behavior in vivo.  
This relationship was further reinforced by results from the same group. Lin et al. investigated the 
effect of the knockdown of these proteins on the expression of EMT markers and showed that 
inhibition of claudin-3 and claudin-4 promotes EMT in ovarian cancer cells through the 
downregulation of E-cadherin, upregulation of Twist, and activation of the PI3K pathway [96]. These 
results are consistent with an increasing body of evidence suggesting that high-grade serous ovarian 
carcinomas arise from the distal fallopian tubes rather than the ovarian surface epithelium [36–38]. In 
contrast to the roles of claudin-3 and claudin-4 in ovarian cancer cells, claudin-1 promotes EMT in 
human liver cells, supporting the notion that the role of claudins in EMT is tissue-specific [67].  
In light of these two recent studies, it may be postulated that ovarian cancers lacking the expression 
of these claudins show a more aggressive and metastatic behavior, which contradicts the previously 
accepted concept that claudin-3 or claudin-4 overexpression in ovarian carcinoma is related to a more 
malignant phenotype of ovarian cancer. However, these recent studies indicating the tumor suppressive 
role of claudin-3 or -4 in ovarian cancer cells are based on results obtained in only one or two cell 
lines. Furthermore, these findings are in conflict with the association of high claudin-3 expression with 
poor prognosis of ovarian cancer patients, including the shorter survival of patients previously reported 
by our group [105]. Therefore, further comprehensive studies are necessary to elucidate the exact role 
of claudin-3 and claudin-4 in ovarian cancer.  
The association between the loss of claudin-3 and claudin-4 and the degree of malignancy of 
ovarian cancer is in line with the known disruption of TJ function during tumorigenesis, and may 
explain the relationship between the claudin-low subtype with low expression of claudin-3, -4 and -7 
and E-cadherin and the aggressive phenotype of breast cancer [11,12]. 
Similarly, the tumor suppressive role of claudin-4 has been described in various cancers. Claudin-4 
expression suppresses cell invasion and metastasis in pancreatic cancer [81]. Our group also showed 
that claudin-4 overexpression inhibits the migration and invasion of gastric cancer cells without 
affecting cell growth [7]. Evidences showing that low claudin-4 expression is linked to poor prognosis 
of patients with breast [106], esophageal [107], colon [108,109] and pancreatic cancers [110] suggest 
that claudin-4 expression is likely to play a tumor suppressive role in several cancers, although its role 
in ovarian cancer remains unclear. 
The function of claudin-3 or claudin-4 is regulated by phosphorylation via kinases as well as by 
forced or knockdown expression. For example, phosphorylation of claudin-3 and claudin-4 by   
PKA [86] or PKC [87] increases paracellular permeability in ovarian cancer cells via mislocalization Int. J. Mol. Sci. 2013, 14 18160 
 
 
of claudins. As in ovarian cancer cells, PKCα activation results in the mislocalization of claudin-4 
along with decreased tight junction barrier integrity in human pancreatic cancer cells [111].  
5.1.3. Claudin-6 
Despite several reports describing claudin-6 expression in multiple human cancers such as rhabdoid 
tumors [112], breast cancer [113] and gastric cancer [114], the function of claudin-6 in cancer cells has 
not been analyzed in detail. One study showed that decreased expression of claudin-6 enhances 
anchorage-independent growth and promotes cellular invasiveness of breast cancer cells [99]. In 
another study [100], claudin-6 expression was associated with decreased anchorage-independent 
growth, invasion, and increased TER in breast carcinoma cells, suggesting a possible tumor 
suppressive role for claudin-6 in breast cancer. On the other hand, claudin-6 overexpression in the 
human gastric cancer cell line AGS increases its invasion, migration, and proliferation potentials [98]. 
A recent study suggested a novel role for claudin-6 as a receptor for CPE by showing that the CPE 
sensitivity of an ovarian cancer cell line that does not express claudin-3 and claudin-4 is decreased in 
response to claudin-6 knockdown, while ovarian cell lines resistant to the effects of CPE can be made 
sensitive through claudin-6 overexpression [115]. However, further studies are required to support the 
role of claudin-6 as CPE receptor.  
5.1.4. Claudin-7 
Claudin-7 is another claudin that is frequently dysregulated in cancer, and several studies have 
reported its role in cancer. Knockdown of claudin-7 expression in esophageal squamous cell carcinoma 
cells induces loss of E-cadherin, along with increased cell growth and enhanced cell invasion [84]. 
Similarly, claudin-7 inhibits the migration and invasion of lung cancer cells through a mechanism 
involving the ERK/MAPK signaling pathway [102].  
By contrast, studies have shown that claudin-7 may promote tumor progression. Claudin-7 
overexpression in colorectal cancer cells disrupts cell polarization, enhances β-catenin/Tcf activity and 
cell proliferation, and thereby promotes tumor formation in vivo in xenograft mice injected with 
claudin-7 overexpressing colorectal cancer cells [80]. The EpCAM-claudin-7 complex rather than 
EpCAM itself was reported to promote in vivo tumor growth [116]. The migration and invasion of 
ovarian cancer cells is also enhanced by claudin-7 overexpression [101]. 
5.1.5. Claudin-11 
Claudin-11, also known as oligodendrocyte-specific protein (OSP), is a major component of central 
nervous system myelin and was shown to be highly regulated during development, suggesting its role 
in the growth and differentiation of oligodendrocytes [117]. However, its function in cancer is not well 
understood. The function of claudin-11 in cancer cells has been mostly associated with its tumor 
suppressor function. Reduced CLDN11 expression is associated with increased invasiveness of gastric 
cancer cells [53]. Claudin-11 decreases the invasiveness of bladder cancer cells [103], and knockdown 
of claudin-11 in glioma stem cells promotes cell proliferation, supporting its tumor suppressor   
function [118].  Int. J. Mol. Sci. 2013, 14 18161 
 
 
5.2. Claudins in Cancer Stem Cells or Tumor-Initiating Cells  
The recently reported involvement of CSC/TICs in tumor recurrence and drug resistance has 
generated much interest in elucidating the molecular mechanism regulating these cell populations [8]. 
Moreover, the EMT process has been involved in the generation of CSC/TICs [9]. Previous studies 
have shown that claudins are involved in the EMT process [91,96], and recent studies showing the 
enrichment of stem-like and EMT features in the claudin-low subtype of breast cancer provided new 
insight into the role of claudins in CSC/TICs [11,12].  
The claudin-low subtype is a recently identified molecular subtype of human breast cancer 
characterized by low expression of tight junction and adherens genes including CLDN3, CLDN4, 
CLDN7 and CDH1 [10]. Most claudin-low tumors are triple-negative breast cancers (TNBCs) which 
lack the expression of estrogen receptor, progesterone receptor and epidermal growth factor receptor 2 
(HER2) and they were found to be distinct from basal-like tumors [12]. However, it is possible that 
mesenchymal features of claudin-low tumors are derived from tumor-associated fibroblast or stromal 
contamination, not from tumor cells, and therefore further evaluation of this subtype is needed to rule 
out this possibility. Although this molecular subtype is not fully characterized at present and there are 
controversies surrounding the concept or presence of this subtype, a growing body of studies has 
suggested the molecular or clinical significance of the claudin-low subtype of breast cancer, as 
described in the following sections.  
First, Hennessy et al. [11] compared the transcriptional profiling of metaplastic breast cancers 
(MBCs), which are an aggressive and chemoresistant subgroup of TNBCs, with other common breast 
cancer subtypes including luminal, HER2-enriched and basal-like cancers and identified that MBCs 
are the most related to the recently identified claudin-low breast tumors. This study also showed that 
MBCs and claudin-low subtype breast tumors have high levels of stem cell and EMT markers, and that 
the transcriptional features of these subtypes are enriched in CD44
+/CD24
−/low breast CSC/TICs. 
Another study by Creighton et al. [17] showed that the CD44
+/CD24
−/low-mammosphere (MS) 
signature is primarily found in the claudin-low molecular subtype. Moreover, an increase in 
CD44
+/CD24
−/low-MS and claudin-low signatures was observed in post-treatment samples after chemo 
or hormone therapy, indicating that remaining breast tumors after conventional treatment are likely to 
be enriched in cell subpopulations with CSC/TIC features. Prat et al. [12] comprehensively analyzed 
the clinical and molecular characteristics of the claudin-low subtype of breast cancer in comparison to 
those of the other subtypes and showed that claudin-low breast tumors are correlated with poor 
prognosis and enriched in mesenchymal and mammary stem cell-like features. More recent study by 
Lehmann et al., [119] identified six TNBC subtypes by analyzing the gene expression profiles of 587 
TNBC cases. Among the six subtypes of TNBC, the mesenchymal stem-like (MSL) subtype was found 
to display low expression of claudin-3, -4, and-7, consistent with claudin-low tumors, indicating that 
this subtype is in part composed of the claudin-low tumors. Collectively, these results may support the 
high association between low claudin expression and the features of mammary CSC/TICs.  
Several recent studies showed the generation of breast CSC/TICs with claudin-low phenotypes. 
Asiedu et al. [120] indicated that cells with breast CSC/TIC phenotypes can be generated through 
TGF-β/TNF-α-mediated EMT in mouse mammary carcinoma cells. These cells showed enhanced   
in vitro self-renewal capacity and in vivo tumorigenicity as well as increased resistance to drug Int. J. Mol. Sci. 2013, 14 18162 
 
 
treatments consistent with the phenotype of CSC/TICs. Furthermore, this study revealed that   
TGF-β/TNF-α-derived breast CSCs/TICs show downregulated expression of genes encoding   
claudins-3, -4 and -7, luminal markers and cytokeratin 18, confirming the generation of claudin-low 
breast CSC/TICs through EMT. More recent studies confirmed that TGF-β can increase the number of 
CSC/TICs in breast cancer cell lines [121] and showed that EMT-inducing transcription factors in 
cooperation with active RAS are sufficient to drive the transformation of human mammalian epithelial 
cells into malignant cells with the features of claudin-low tumors in transgenic mice [122]. However, it 
is not yet demonstrated whether loss of claudin expression has a causative role in the generation of 
breast CSC/TICs via EMT or claudin-low subtype of breast cancer is just a secondary consequence of 
disruption of cell-cell junctions and loss of cell polarity during EMT independent of its effects on 
CSC/TICs. Further investigations are required to elucidate the role or functional significance of 
claudins in breast CSC/TICs. 
The potential role of claudins in the regulation of CSC/TICs has also been reported in other cancers. 
First, knockdown of claudin-4 expression in ovarian cancer cells delayed spheroid formation, 
suggesting the involvement of claudin-4 in the regulation of spheroid formation [123]. In addition, 
microarray analysis comparing gene expression between CD133
+CD117
+ primary ovarian sphere cells 
and differentiated cells identified claudin-1 as one of the genes significantly upregulated in ovarian 
CSC/TICs, suggesting the possible role of claudin-1 in ovarian CSC/TICs [15]. Based on these 
findings, the same group showed that miR-155 downregulates claudin-1 expression at the mRNA and 
protein levels by targeting its mRNA in ovarian CSC/TICs [16]. This study also showed that miR-155 
overexpression significantly suppresses the proliferation and invasion of ovarian CSC/TICs in vitro 
and the growth of ovarian CSC/TIC xenograft tumors in vivo. These results indicate that miR-155 
suppresses the proliferation of ovarian CSC/TICs by downregulating claudin-1 expression and provide 
further evidence supporting the role of claudin-1 in ovarian CSC/TICs. Independent of its effect on 
CSC/TICs, overexpressed miR-155 in colorectal cancer cells promotes the migration and invasion of 
cells through the upregulation of claudin-1 expression [124]. 
Unlike other claudins, claudin-6 is expressed at higher levels in undifferentiated mouse stem cells 
than in non-stem cells [125] and plays an important role in the development of the mouse embryonic 
epithelium [126]. Claudin-6 is also highly expressed in human undifferentiated cells and is necessary 
for human pluripotent stem cell survival and self-renewal [127]. These findings support the crucial role 
of claudin-6 in the function of human pluripotent stem cells and suggest its value as a stem   
cell-specific marker and as a target for the elimination of undifferentiated cells from mixed cell 
populations. Given its role in the function of pluripotent stem cells, claudin-6 is likely to play a role in 
CSC/TICs. Therefore, further studies investigating the involvement of claudin-6 in CSC/TICs are 
necessary to understand its role in their regulation. 
Claudin-11 significantly inhibits the growth of glioma stem-like cells [118], and the expression of 
claudin-11 is regulated by miR-1275, indicating the importance of epigenetic mechanism in the 
regulation of glioma stem-like cells. 
The relevance of claudins in CSC/TICs is beginning to emerge, and further investigation aimed at 
elucidating their function in CSC/TICs may support the notion that claudins are promising targets for 
the regulation of CSC/TICs in the treatment of recurrent cancers.  Int. J. Mol. Sci. 2013, 14 18163 
 
 
5.3. Claudins in Chemoresistance 
Resistance to chemotherapy is the main cause of treatment failure in many cancers [128]. Thus, 
identifying cancer chemoresistance-associated genes or pathways is critical for the successful 
treatment of cancer.  
As the development of effective therapies against chemoresistant tumors is a high priority in 
ovarian cancer, several studies have focused on the identification of chemoresistance-associated genes 
or pathways. To identify proteins associated with cisplatin resistance in ovarian cancer,   
Stewart  et al. [129] compared the expression of 1117 proteins between cisplatin-sensitive and   
-resistant ovarian cancer cells using quantitative proteomics technology and identified 121 proteins 
differentially expressed between the two cell lines. Of note, claudin-4 was overexpressed by 7.2-fold in 
cisplatin-resistant cells and was one of the most overexpressed proteins, suggesting its possible 
association with cisplatin resistance in ovarian cancer.  
Consistent with this study, several lines of evidence support the association of high claudin-4 
expression with chemoresistance of ovarian cancer. A recent study by a Japanese group [130] reported 
that ovarian cancer tissues from platinum-resistant patients have higher levels of claudin-4 expression 
than those from chemosensitive patients, and suppression of claudin-4 increased the sensitivity of 
ovarian cancer cells to cisplatin. Furthermore, higher claudin-4 gene expression was also observed in 
chemoresistant CD44
+ ovarian CSC/TICs [131]. 
Another study showed that the expression of claudin-3 and claudin-4, which are CPE receptors, is 
significantly higher in chemotherapy-resistant/recurrent ovarian tumors than in chemotherapy-naive 
ovarian cancers, and that targeting these proteins by CPE-mediated therapy may be effective in killing 
chemoresistant/recurrent ovarian tumors in vitro and in vivo [132].  
In addition to claudin-3 and claudin-4, claudin-7 expression is also involved in the response to 
platinum-based chemotherapy. Kim et al. [133] reported that high claudin-7 protein expression is 
significantly associated with shorter progression-free survival and poor sensitivity to platinum-based 
chemotherapy in ovarian cancer patients. In line with these clinical observations, claudin-7 knockdown 
was shown to increase the sensitivity of ovarian cancer cells to cisplatin treatment in this study. These 
findings were supported by a report showing that EpCAM-associated claudin-7 promotes drug 
resistance in a rat pancreatic cancer cell line [134]. 
Taken together, these results indicated that the expression of claudins, including claudin-3, -4 and  
-7, is higher in chemoresistant than in chemosensitive ovarian cancer cells and that their high 
expression is associated with increased resistance to chemotherapy in ovarian cancer, highlighting the 
fact that targeting these claudins using CPE or siRNA may increase the sensitivity of ovarian cancer 
cells to chemotherapy.  
However, the opposite results on the association of these claudins with chemoresistance have been 
recently reported by a growing number of studies. Shang et al. [18] showed that knockdown of 
claudin-3 or claudin-4 increases the resistance to cisplatin in ovarian cancer cells in vitro and in vivo. 
Furthermore, these authors investigated the molecular mechanism by which claudin-3 or claudin-4 
affect cisplatin sensitivity by assessing the changes in the expression of Cu transporters and 
chaperones based on previous studies showing their role in the sensitivity of ovarian cancer cells to 
cisplatin. The results showed that the effect of claudin-3 or claudin-4 on the sensitivity of ovarian Int. J. Mol. Sci. 2013, 14 18164 
 
 
cancer cells to cisplatin is mediated in part by the regulation of the expression of the copper and 
cisplatin influx transporter CTR1. CTR1 gene expression was reduced in CLDN3 or CLDN4 
knockdown cells, and enforced CTR1 expression restored their sensitivity to cisplatin, indicating that 
CTR1 plays a role in cisplatin sensitivity in ovarian cancer cells.  
Similarly, a recent study on human lung cancer cells showed that claudin-7 increases 
chemosensitivity to cisplatin by activating caspase pathways [135], which is in contrast to the study by 
Kim et al. [133] that showed an association between high claudin-7 expression and poor sensitivity to 
platinum-based chemotherapy in ovarian cancer. In this study, claudin-7-transfected cells showed a 
remarkable increase in the rate of cell apoptosis and significantly decreased cell viability. Cisplatin 
treatment increased the levels of cleaved caspases and PARP in claudin-7-transfected cells compared 
to non-transfected cells, indicating that increased chemosensitivity in claudin-7-expressed cells is 
related to the caspase pathway. 
Emerging evidence on the association of CSC/TICs with chemoresistance suggests that the reduced 
levels of claudin-3, -4, or -7 expression in ovarian cancer cells is related to increased resistance to 
chemotherapy based on recent studies showing that reduced claudin-3 or claudin-4 promote EMT in 
ovarian cancer cells [96]. The association of low claudin expression with resistance to chemotherapy is 
supported by a recent study showing that subpopulations of CD44
+/CD24
−/low breast cancer cells with 
high CSC/TIC potential and a claudin-low subtype are enriched in residual tumors after conventional 
chemotherapy, which is in line with the expectation of survival of CSC/TICs after treatment [17]  
and indicates that the claudin-low subtype of breast cancer is associated with increased resistance  
to chemotherapy.  
In addition to the aforementioned claudins, including claudin-3, -4 and -7, accumulating evidences 
support the link between reduced claudins and increased resistance to chemotherapy of cancer cells. To 
identify specific signaling pathways associated with platinum resistance in ovarian cancer,   
Li et al. [136] performed an integrated analysis of global DNA methylation and gene expression in 
cisplatin-sensitive or -resistant ovarian cancer cells. A series of drug-resistant ovarian cancer cells 
were established by successive cisplatin treatments in the drug-sensitive A2780 ovarian cancer cell 
line. Promoter DNA methylation analyses showed an increase in the number of hypermethylated CpG 
islands and GI50 values (i.e., dose necessary for 50% growth inhibition) with successive cisplatin 
treatment cycles, indicating the positive correlation between DNA methylation and the development of 
cisplatin resistance. Furthermore, pathway enrichment analysis identified several key biological 
pathways repressed by DNA hypermethylation or activated by DNA hypomethylation, and CLDN11 
was identified as one of the genes involved in pathways repressed by DNA hypermethylation during 
the development of cisplatin resistance.  
Consistent with these results, reduced claudin-1 expression was associated with increased 
chemoresistance of epithelial cancer cells [137] in a study in which stable knockdown of keratin 8 and 
18 increased cisplatin-induced apoptosis through claudin-1 upregulation, suggesting that increased 
claudin-1 expression may increase cisplatin sensitivity [137].  
Taken together, these studies indicate that claudins contribute to drug resistance in cancer cells via 
their effects on drug transporters, apoptosis or CSC/TICs, although the exact underlying mechanism is 
not well understood. In addition, the differences in the relationship between claudins and 
chemoresistance according to cancer type and the reason behind the reported opposite results on the Int. J. Mol. Sci. 2013, 14 18165 
 
 
function of the same claudin remain unclear. Thus, further comprehensive studies are required to shed 
light on the relevance and role of claudins in chemoresistance. 
In summary, the recent emerging roles of claudins in EMT, CSC/TICs and chemoresistance suggest 
the existence of a link between claudins, EMT, CSC/TICs and chemoresistance (Figure 1).  
Figure 1. Proposed emerging role of claudins in epithelial to mesenchymal transition 
(EMT), cancer stem cells or tumor-initiating cells (CSC/TICs), and chemoresistance   
or recurrence. 
 
6. Claudins as Biomarkers and Therapeutic Targets 
6.1. Prognostic Significance of Claudins in Cancer  
The highly specific claudin expression patterns in human cancer tissues suggest that claudins may 
be useful biomarkers for the detection, diagnosis, and treatment of cancers. Among claudin proteins, 
claudin-3 and claudin-4 have been shown to be highly upregulated in ovarian carcinoma compared to 
normal ovarian surface epithelium in several studies [57,58,61,62]. Because of their consistent 
overexpression in ovarian cancer, claudin-3 and claudin-4 have been suggested as potentially useful 
biomarkers for the detection and diagnosis of ovarian cancer. Recently, claudin-4 was detected in the 
peripheral circulation of ovarian cancer patients, further supporting its usefulness as a biomarker [138].  
Claudin expression has also been reported as a prognostic indicator as dysregulated claudin 
expression is associated with the prognosis of cancer patients (Table 4).  
Low expression of claudin-1 is associated with poor patient prognosis in several cancers, including 
stage II colon cancer [139] and prostate cancer [65], and it is an independent predictor of tumor 
recurrence in both cancer types. Decreased claudin-1 expression is an indicator of the degree of 
malignancy of hepatocellular carcinoma as suggested by its correlation with dedifferentiation and 
portal invasion [54]. Similarly, decreased claudin-1 expression is positively correlated with the 
frequency of recurrence and shorter disease-free intervals in breast cancer [140]. Claudin-1 expression 
is upregulated in association with older age in women with basal-like breast cancer, suggesting the 
potential value of claudin-1 for the identification of specific groups of patients with basal-like breast 
cancer [88].  Int. J. Mol. Sci. 2013, 14 18166 
 
 
Table 4. Clinical significance of claudin expression in human cancers.  
Claudins Cancer  types 
Association of claudin protein expression 
based on IHC and patient survival 
Prognosis 
Independent 
prognostic factor 
Reference 
Claudin-1 
Breast Low  expression→shorter disease-free interval  Low→poor   [140] 
Colon 
Low expression→shorter overall survival and 
disease-free survival 
Low→poor 
Independent predictor of 
recurrence and positive 
prognostic factor 
[139] 
Colorectal 
Low expression→shorter cancer-specific and 
disease-free survival 
Low→poor   [109] 
Prostate 
Low expression→shorter recurrence-free 
survival 
Low→poor 
Independent predictor of 
recurrence 
[65] 
Claudin-3 
Breast 
Positive expression→shorter disease-free 
survival (triple-negative)  
Positive expression→longer disease-free 
survival (luminal) 
High→poor 
(triple-negative) 
High→better 
(luminal ) 
 [141] 
Ovarian High  expression→shorter survival  High→poor 
Independent negative 
prognostic factor 
[105] 
Claudin-4 
Breast 
High expression→shorter cancer-specific 
survival, overall survival and recurrence-free 
survival 
High→poor 
Independent negative 
prognostic factor 
[142] 
Breast 
Positive expression→longer disease-free 
survival (triple-negative)  
Positive expression→shorter disease-free 
survival (luminal type) 
High→better 
(triple-negative) 
High→poor 
(luminal ) 
 [141] 
Colorectal 
Low expression shorter cancer-specific and 
disease-free survival 
Low→poor   [109] 
Esophageal 
Twist1 high/claudin-4 low expression→shorter 
overall survival 
Twist1 
high/claudin-4 
low→poor 
Independent positive 
prognostic factor 
[107] 
Gastric 
Moderate to strong staining→shorter overall 
survival 
High→poor 
Independent negative 
prognostic factor 
[41] 
Gastric 
High membranous expression→longer overall 
survival 
High→better 
Independent positive 
prognostic factor 
[7] 
Pancreatic 
Low gene expression *→shorter overall 
survival 
Low→poor 
Independent positive 
prognostic factor 
[110] 
Claudin-7 
Breast 
Positive expression→shorter recurrence-free 
survival 
High→poor   [143] 
Lung Low  expression→shorter overall survival  Low→poor   [144] 
Oral Positive  expression→better prognosis  High→better   [145] 
Claudin-10 Liver 
High gene expression *→shorter disease-free 
survival 
High→poor 
Independent prognostic 
factor for disease 
recurrence 
[146] 
IHC: Immunohistochemistry.* Claudin gene expression by qRT-PCR. Int. J. Mol. Sci. 2013, 14 18167 
 
 
Similarly, the downregulation of claudin-2 protein expression is significantly associated with a high 
clinical stage of patients with breast cancer [43].  
By contrast, ovarian serous adenocarcinoma patients with high claudin-3 expression show a 
significantly shorter survival than those with low claudin-3 expression, while claudin-4 expression is 
not associated with patient survival in this cancer [105]. Therefore, claudin-3 overexpression is an 
independent negative prognostic factor in ovarian serous carcinoma. Claudin-3 and claudin-4 
overexpression in this study was determined by their non-detectable expression in normal ovarian 
surface epithelium based on the notion that ovarian cancer originates in the normal ovarian surface 
epithelium [105].  
A study investigating the clinical significance of claudin-4 in breast cancer showed that high 
claudin-4 expression is associated with significantly shorter overall survival and recurrence-free 
survival, suggesting a relationship between high claudin-4 expression and poor outcomes of patients 
with breast cancer [142]. However, recent studies have shown that the distinct prognostic significance 
of claudin-3 or claudin-4 is dependent on the subtype of breast cancer. For instance, a Japanese group 
showed that the combination of claudin-4 and E-cadherin expression called CURIO accurately predicts 
relapse-free survival in breast cancer [106]. CURIO was shown to predict prognosis, especially in 
luminal A and triple-negative subtypes of breast cancer: high expression of CURIO is related to worse 
prognosis and low expression is associated with a better outcome. The distinctive prognostic 
significance of claudin-3 and claudin-4 in triple-negative and luminal types of breast cancer was 
analyzed in a recent report [141] in which positive expression of claudin-3 was associated with poor 
prognostic factors, whereas claudin-4 expression was related to better prognostic factors in   
TNBCs. Conversely, positive claudin-4 expression was associated with shorter disease-free survival 
and claudin-3 was related to longer disease-free survival in luminal types of breast cancer.  
The relationship of claudin-4 expression with patient prognosis in gastric cancer is also 
controversial. One study [41] showed that strong claudin-4 expression is more frequently associated 
with the intestinal type than the diffuse type of gastric cancer, and high claudin-4 expression is 
significantly associated with shorter survival, while another study [147] showed that overall survival is 
decreased in patients with low claudin-4 expression. Our group recently reported that high 
membranous claudin-4 expression is related to better prognosis, while cytoplasmic claudin-4 
expression has no significant relationship with patient prognosis [7]. Importantly, this study 
demonstrated that high membranous claudin-4 expression is an independent positive prognostic factor 
in gastric carcinoma. 
Low expression of claudin-4 is related to poor prognosis in esophageal cancer [107], colon   
cancer [108], colorectal cancer [109], and pancreatic carcinoma [110]. 
Reduced expression of claudin-7 is associated with poor patient outcome in several cancers. 
Comparison of the expression of claudin-7 at the invasive front of the esophageal cancer with that in 
the corresponding metastastic lymph nodes showed significantly reduced claudin-7 expression in 
metastastic lymph nodes, indicating that claudin-7 may be a predictor of lymph node metastasis [50]. 
Loss of claudin-7 expression is significantly correlated with high histological grade of breast 
carcinoma, including ductal carcinoma in situ and invasive ductal carcinoma [45]. A recent study 
further supported the poor prognostic significance of claudin-7 expression in ductal invasive breast 
cancer by showing that claudin-7 expression is associated with a shorter time to recurrence [143]. In Int. J. Mol. Sci. 2013, 14 18168 
 
 
non-small cell lung cancer, survival is significantly poorer in patients with low claudin-7 expression 
than in those with high claudin-7 expression [144]. Decreased claudin-7 expression is also correlated 
with unfavorable prognostic factors, including invasion and lymph node metastasis, whereas patients 
with positive claudin-7 expression show a significantly favorable prognosis in oral squamous cell 
carcinoma [145].  
The combined expression of several claudins can predict disease recurrence, as shown in a recent 
study by Lu et al. [13] in which the relationship between the expression of claudins -1, -3, -4, -7 and  
-8 and patient survival was analyzed in high-grade invasive breast cancer including several molecular 
subtypes. In this study, low expression of all five claudins was mostly detected in basal-like cancers 
(77%), and patients with claudin-low tumors had significantly shorter recurrence-free survival, 
suggesting that low levels of claudin expression predict disease recurrence. 
An association between claudin-10 gene expression and disease recurrence in hepatocellular 
carcinoma was suggested by the finding that patients with high expression of claudin-10 had shorter 
disease-free survival [146]. Multivariate analysis confirmed that claudin-10 gene expression is an 
independent predictor in recurrence of hepatocellular carcinoma. 
6.2. Claudins as Drug Targets in Cancer  
Claudins have four transmembrane domains and two extracellular loops, and they are promising 
targets for antibody-based therapies. However, their hydrophobicity and low immunogenicity has 
made it difficult to raise antibodies targeting claudins. Antibodies that specifically recognize the 
extracellular loops of human claudin-3 [148] or claudin-4 [149] have been successfully produced, and 
the anti-claudin-4 antibody has shown therapeutic antitumor activity in vitro and in vivo [149]. 
Furthermore, a dual-targeting monoclonal antibody against claudin-3 and claudin-4 was recently 
prepared and shown to possess antitumor effects in vitro and in vivo [150], supporting the potential 
role of claudins as targets for therapeutic antibodies. This antibody successfully induced   
antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC)   
in vitro and inhibited tumor formation in SCID mice in vivo.  
Claudin-3 and claudin-4 are receptors for CPE; therefore, the use of CPE to target claudins has been 
suggested. CPE treatment of ovarian cancer cells affects TJ function [75], and treatment with 
recombinant CPE fused to tumor necrosis factor has cytotoxic effects in ovarian cancer cells, 
supporting the possible development of CPE as targeted therapy for ovarian cancer [151]. Especially, 
CPE is effective in chemoresistant/recurrent ovarian cancer based on the high expression of claudin-3 
and claudin-4 in chemoresistant/recurrent ovarian tumors [132].  
On the other hand, studies have shown the therapeutic effects of siRNAs targeting claudin. CLDN3 
siRNA showed potent suppression of both tumor growth and metastasis in mouse and human ovarian 
tumor xenografts [95]. 
Taken together, the results of previous studies suggest that claudin-targeted drugs and therapies for 
cancer treatment are likely to be clinically applicable in the near future, although proof of concept for 
claudin-targeted therapy is not yet fully established.  Int. J. Mol. Sci. 2013, 14 18169 
 
 
7. Conclusions  
The generally accepted concept that tumorigenesis is associated with loss of function of TJs implies 
that claudin expression is downregulated during tumor progression. However, claudin expression can 
be decreased or increased in human cancer in a tissue-specific manner, and a role for claudins in tumor 
progression has been suggested based on their effects on the migration and invasion of cancer cells and 
metastasis. Furthermore, claudin expression is significantly associated with patient survival or 
recurrence in some cancers, suggesting that these TJ proteins could be prognostic markers and 
promising therapeutic targets, although their exact role in cancer remains to be elucidated. 
The recent identification of a claudin-low subtype of breast carcinoma characterized by enrichment 
of EMT markers and stem cell-like features has suggested a potentially important role for claudins in 
the acquisition of a CSC/TIC phenotype through EMT. Recent studies provided further evidence 
supporting the EMT-induced generation of breast CSC/TICs with claudin-low expression and the 
relevance of the claudin-low subtype in chemoresistance. In this context, a link between claudin, EMT, 
CSC/TICs and chemoresistance has been suggested. A critical issue in the current treatment of cancer 
is the association between the development of CSC/TICs and resistance to current chemotherapy and 
recurrence after initial treatment. Therefore, a better understanding of the role of claudins in EMT and 
CSC/TICs may provide important information to elucidate the molecular mechanisms of   
tumor recurrence and may help in the design of therapeutic strategies for chemoresistant and   
recurrent cancers. 
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